AMR Stakeholder Profile
Focus area/active in: Human Health | Therapeutics
Company/Organisation type: SME
Juvabis is a clinical-stage Swiss biopharmaceutical start-up that addresses the global challenge of life-threatening bacterial infections by designing and developing next-generation aminoglycoside-antibiotics. Juvabis aims to treat antibiotic-resistant infections with aminoglycoside-therapies of unprecedented safety and efficacy. Juvabis’ best-in-class clinical-candidate apramycin is currently in Phase 1 first-in-human trials, being developed in partnership with the Innovative Medicines Initiative.
Get in touch!
Head of Business Development
Please fill out the form below to get in touch with us.